Literature DB >> 21356359

Loss of endogenous bone morphogenetic protein-6 aggravates renal fibrosis.

Amélie Dendooven1, Olivia van Oostrom, Dionne M van der Giezen, Jan Willem Leeuwis, Cristel Snijckers, Jaap A Joles, Elizabeth J Robertson, Marianne C Verhaar, Tri Q Nguyen, Roel Goldschmeding.   

Abstract

Bone morphogenetic protein-6 (BMP-6) suppresses inflammatory genes in renal proximal tubular cells and regulates iron metabolism by inducing hepcidin. In diabetic patients, an increase of myofibroblast progenitor cells (MFPCs), also known as fibrocytes, was found to be associated with decreased BMP-6 expression. We hypothesized that loss of endogenous BMP-6 would aggravate renal injury and fibrosis. Wild type (WT) and BMP-6 null mice underwent unilateral ureteral obstruction. In WT mice, ureteral obstruction down-regulated BMP-6. Obstructed kidneys of BMP-6 null mice showed more casts (1.5-fold), epithelial necrosis (1.4-fold), and brush border loss (1.3-fold). This was associated with more inflammation (1.8-fold more CD45(+) cells) and more pronounced overexpression of profibrotic genes for αSMA (2.0-fold), collagen I (6.8-fold), fibronectin (4.3-fold), CTGF (1.8-fold), and PAI-1 (3.8-fold), despite similar BMP-7 expression. Also, 1.3-fold more MFPCs were obtained from BMP-6 null than from WT mononuclear cell cultures, but in vivo only very few MFPCs were observed in obstructed kidneys, irrespective of BMP-6 genotype. The obstructed kidneys of BMP-6 null mice showed 2.2-fold more iron deposition, in association with 3.3-fold higher expression of the oxidative stress marker HO-1. Thus, ureteral obstruction leads to down-regulation of BMP-6 expression, and BMP-6 deficiency aggravates tubulointerstitial damage and fibrosis independent of BMP-7. This process appears to involve loss of both direct anti-inflammatory and antifibrotic action and indirect suppressive effects on renal iron deposition, oxidative stress, and MFPCs.
Copyright © 2011 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21356359      PMCID: PMC3070547          DOI: 10.1016/j.ajpath.2010.12.005

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  50 in total

Review 1.  Specificity, diversity, and regulation in TGF-beta superfamily signaling.

Authors:  E Piek; C H Heldin; P Ten Dijke
Journal:  FASEB J       Date:  1999-12       Impact factor: 5.191

2.  Fibrocytes from burn patients regulate the activities of fibroblasts.

Authors:  Jian Fei Wang; Haiyan Jiao; Tara L Stewart; Heather A Shankowsky; Paul G Scott; Edward E Tredget
Journal:  Wound Repair Regen       Date:  2007 Jan-Feb       Impact factor: 3.617

Review 3.  Oxidants in chronic kidney disease.

Authors:  Sudhir V Shah; Radhakrishna Baliga; Mohan Rajapurkar; Vivian A Fonseca
Journal:  J Am Soc Nephrol       Date:  2006-12-13       Impact factor: 10.121

4.  Renal fibrosis and glomerulosclerosis in a new mouse model of diabetic nephropathy and its regression by bone morphogenic protein-7 and advanced glycation end product inhibitors.

Authors:  Hikaru Sugimoto; Gordan Grahovac; Michael Zeisberg; Raghu Kalluri
Journal:  Diabetes       Date:  2007-04-24       Impact factor: 9.461

5.  Inhibitory effects and target genes of bone morphogenetic protein 6 in Jurkat TAg cells.

Authors:  Einar A Sivertsen; Kanutte Huse; Marit E Hystad; Christian Kersten; Erlend B Smeland; June H Myklebust
Journal:  Eur J Immunol       Date:  2007-10       Impact factor: 5.532

6.  Kidney fibrosis in hypertensive rats: role of oxidative stress.

Authors:  Wenyuan Zhao; Sue S Chen; Yuanjian Chen; Robert A Ahokas; Yao Sun
Journal:  Am J Nephrol       Date:  2008-02-01       Impact factor: 3.754

7.  CTGF inhibits BMP-7 signaling in diabetic nephropathy.

Authors:  Tri Q Nguyen; Peggy Roestenberg; Frans A van Nieuwenhoven; Niels Bovenschen; Zeke Li; Leon Xu; Noelynn Oliver; Jan Aten; Jaap A Joles; Cecilia Vial; Enrique Brandan; Karen M Lyons; Roel Goldschmeding
Journal:  J Am Soc Nephrol       Date:  2008-07-16       Impact factor: 10.121

8.  Dendritic cells facilitate accumulation of IL-17 T cells in the kidney following acute renal obstruction.

Authors:  Xiangyang Dong; Lori A Bachman; Melinda N Miller; Karl A Nath; Matthew D Griffin
Journal:  Kidney Int       Date:  2008-08-13       Impact factor: 10.612

Review 9.  Bone morphogenetic protein-7 and connective tissue growth factor: novel targets for treatment of renal fibrosis?

Authors:  Tri Q Nguyen; Roel Goldschmeding
Journal:  Pharm Res       Date:  2008-02-12       Impact factor: 4.200

Review 10.  The role of the fibrocyte, a bone marrow-derived mesenchymal progenitor, in reactive and reparative fibroses.

Authors:  Alberto Bellini; Sabrina Mattoli
Journal:  Lab Invest       Date:  2007-07-02       Impact factor: 5.662

View more
  28 in total

1.  BMP-6 emerges as a potential major regulator of fibrosis in the kidney.

Authors:  Robert H Jenkins; Donald J Fraser
Journal:  Am J Pathol       Date:  2011-03       Impact factor: 4.307

2.  Tumor Endothelial Cells with Distinct Patterns of TGFβ-Driven Endothelial-to-Mesenchymal Transition.

Authors:  Lin Xiao; Dae Joong Kim; Clayton L Davis; James V McCann; James M Dunleavey; Alissa K Vanderlinden; Nuo Xu; Samantha G Pattenden; Stephen V Frye; Xia Xu; Mark Onaitis; Elizabeth Monaghan-Benson; Keith Burridge; Andrew C Dudley
Journal:  Cancer Res       Date:  2015-01-29       Impact factor: 12.701

3.  Distinct bone morphogenetic proteins activate indistinguishable transcriptional responses in nephron epithelia including Notch target genes.

Authors:  Barry W Larman; Michele J Karolak; Volkhard Lindner; Leif Oxburgh
Journal:  Cell Signal       Date:  2011-09-16       Impact factor: 4.315

4.  Loss of expression of protein phosphatase magnesium-dependent 1A during kidney injury promotes fibrotic maladaptive repair.

Authors:  Rohan Samarakoon; Alexandra Rehfuss; Nidah S Khakoo; Lucas L Falke; Amy D Dobberfuhl; Sevann Helo; Jessica M Overstreet; Roel Goldschmeding; Paul J Higgins
Journal:  FASEB J       Date:  2016-06-21       Impact factor: 5.191

5.  Dragon (repulsive guidance molecule RGMb) inhibits E-cadherin expression and induces apoptosis in renal tubular epithelial cells.

Authors:  Wenjing Liu; Xiaoling Li; Yueshui Zhao; Xiao-Ming Meng; Chao Wan; Baoxue Yang; Hui-Yao Lan; Herbert Y Lin; Yin Xia
Journal:  J Biol Chem       Date:  2013-09-19       Impact factor: 5.157

6.  BMP pathway suppression is an early event in inflammation-driven colon neoplasmatogenesis of uPA-deficient mice.

Authors:  George S Karagiannis; Hara Afaloniati; Elisavet Karamanavi; Theofilos Poutahidis; Katerina Angelopoulou
Journal:  Tumour Biol       Date:  2015-09-10

7.  Expression of bone morphogenetic proteins 4, 6 and 7 is downregulated in kidney allografts with interstitial fibrosis and tubular atrophy.

Authors:  Vesna Furic-Cunko; Petar Kes; Marijana Coric; Tvrtko Hudolin; Zeljko Kastelan; Nikolina Basic-Jukic
Journal:  Int Urol Nephrol       Date:  2015-05-12       Impact factor: 2.370

8.  Genome-wide comparative analysis ofbone morphogenetic proteins: genomic structure, phylogeny, and expression patterns in the golden pompano,Trachinotus ovatus(Linnaeus, 1758).

Authors:  Jinhui Sun; Kecheng Zhu; Huayang Guo; Nan Zhang; Shigui Jiang; Dianchang Zhang
Journal:  Fish Physiol Biochem       Date:  2019-11-03       Impact factor: 2.794

9.  Bone morphogenetic protein signaling in vascular disease: anti-inflammatory action through myocardin-related transcription factor A.

Authors:  Dahai Wang; Jamunabai Prakash; Peter Nguyen; Brandi N Davis-Dusenbery; Nicholas S Hill; Matthew D Layne; Akiko Hata; Giorgio Lagna
Journal:  J Biol Chem       Date:  2012-06-20       Impact factor: 5.157

10.  A 190 base pair, TGF-β responsive tooth and fin enhancer is required for stickleback Bmp6 expression.

Authors:  Priscilla A Erickson; Phillip A Cleves; Nicholas A Ellis; Kevin T Schwalbach; James C Hart; Craig T Miller
Journal:  Dev Biol       Date:  2015-02-27       Impact factor: 3.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.